Know Labs, Inc. (OTCQB: KNWN) is a technology company that specializes in the development of proprietary technologies that use electromagnetic energy to detect and identify a wide variety of substances. Shares jumped 107% on Wednesday, July 11, 2018. Over the past 30 days, Know Labs, Inc. has seen an average daily volume of 23,500 shares. However on Wednesday, over 313,000 shares traded hands, which equates to almost $461,000 in dollar volume.
Shares surged on Wednesday after Know Labs, Inc. announced they have developed a new technology capable of non-invasively measuring blood glucose levels. Currently, a finger prick is necessary for the 366 million around the world with diabetes, and it was the goal of Know Labs, Inc. to eliminate this painful procedure. By 2045, the number of diabetics is expected to grow to over 629 million worldwide, making this low-cost, wearable technology more important than ever. In the announcement, CEO Phil Bosua said the initial bench tests went much better than expected and that the company will continue to release updates, along with their research and findings, in the coming weeks. Here is the full press release detailing the new technology:
Know Labs, Inc. Press Release:
Know Labs, Inc. (f/k/a Visualant, Incorporated) (OTCQB: KNWN) – a provider of identification, authentication and diagnostic solutions, released today a video of the Company’s invention of a new technology to detect blood glucose non-invasively. In the video, Company CEO Phil Bosua briefly discusses the breakthrough.
The transcript of Phil Bosua’s narrative in the video states in part:
“We’re developing a brand-new technology platform that measures blood glucose – non-invasively. Our bench tests are proving to be better than expected and we’re really excited about the future.”
Link to video: http://bit.ly/Know-Labs-Invents-New-Way-To-Detect-Blood-Glucose-Non-Invasively
About Know Labs, Inc.
Know Labs, Inc. (f/k/a Visualant Incorporated) is a public company whose shares currently trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at www.knowlabs.co
This video at the link above and this release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words may, would, will, expect, estimate, can, believe, potential and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
